MedWatch

Analyst: Discouraging announcement from Sonova puts spotlight on GN

The hearing aid giant’s downgrade could potentially impact its Danish competitors, says a Sydbank analyst.

Photo: Arnd Wiegmann/Reuters/Ritzau Scanpix

The world’s biggest hearing aid manufacturer, Swiss Sonova, on Tuesday downgraded its full-year expectations for 2022/2023, citing a weak private market in the US and high freight and component costs.

In particular, the developments in the US are worrying when it comes to some of Sonova’s competitors based in Denmark, says Sydbank analyst Søren Løntoft Hansen.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs